BOLT · NASDAQ
Bolt Biotherapeutics, Inc.
$6.68 +0.41 (+6.54%)
Company overview
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company developing immuno-oncology agents designed to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2) targeting agent in a Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program designed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. Bolt Biotherapeutics is also developing a programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $12.9M
- Employees
- 52
- Headquarters
- Redwood City, CA
- Website
- boltbio.com
- CEO
- William Quinn
- Listed
- February 5, 2021
- P/E
- -0.42
- Dividend yield
- 0.06%
Company financials
- Revenue
- $6.5M
- Gross profit
- $6.3M
- Operating income
- -$30.1M
- EBITDA
- -$29M
- Net income
- -$29.6M
- EPS
- -$15.89
- Total assets
- $48M
- Total debt
- $22.3M
- Gross margin
- 96.88%
- Net margin
- -455.15%
- Earnings yield
- -237.16%
BOLT
1D
NASDAQ
O6.98H7.78L5.99C6.27+2.08 (+49.64%)Vol12.88M